Our vision

At TOLREMO, we address transcriptional non-oncogene addiction both as monotherapy and as combination regimens to transform targeted cancer treatments into long-term therapeutic solutions. By targeting transcriptional cell states, our goal is to arm physicians with novel anti-cancer therapies for better treatment success for their patients.

We are advancing our lead compound TT125-802, a best-in-class CBP/p300 bromodomain inhibitor, as monotherapy and in combination with targeted agents in solid tumors and haematological malignancies.


Leadership


Board of Directors


Scientific Advisory Board


In memoriam


Investors